Eiger BioPharmaceuticals Inc (Nasdaq: EIGR), a company focused on the development and commercialisation of targeted therapies for rare and ultra-rare diseases, announced yesterday that it has named Sri Ryali as its new chief financial officer.

Ryali brings more than fifteen years of finance and commercial experience to Eiger. He was most recently at Aimmune Therapeutics Inc, where he was vice president of Finance, responsible for building and leading the finance department from Aimmune's 2015 initial public offering, and subsequently was a key executive involved in operational preparation for product approval. Earlier, he led US Financial Planning and Analysis at Jazz Pharmaceuticals and was head of Corporate Finance at Onyx Pharmaceuticals Inc, until the company was acquired by Amgen Inc in 2013. Following the acquisition, he continued as head of R&D, Technical Operations, and Medical Affairs Finance at Onyx. He began his career in biopharmaceutical companies at Amgen Inc, where he held positions of increasing responsibility in the finance organisation.

David Cory, Eiger president and chief executive officer, said, 'Eiger is now a late stage biopharmaceutical company with sites activating in our international Phase 3 D-LIVR study in Hepatitis Delta Virus infection and preparation of an NDA for Progeria with plans to file in 2019. We expect Sri's background and recent relevant experience in commercial stage preparation and management, and financial operations in public pharma companies to strengthen Eiger and the executive team as we advance our pipeline.'